- Corporate
Anti-Infectives 2004
- Anderegg TR, Jones RN, Sader HS.
Quality Control Working Group.
Quality control guidelines for
BAL9141 (Ro 63-9141), an
investigational cephalosporin, when
reference MIC and standardized disk
diffusion susceptibility test methods
are used. J Clin Microbiol. 2004;
42(7): 3356–8.
- Appelbaum P, Hoellman D, Jacobs
M. MIC determination of the
anti-pneumococcal activity of BAL9141
compared to other agents. 14th ECCMID
2004. Poster
P537.
- Azoulay-Dupuis E, Bedos JP,
Mohler J, Schmitt-Hoffmann A,
Schleimer M, Shapiro S. Efficacy of
BAL5788, a prodrug of cephalosporin
BAL9141, in a mouse model of acute
pneumococcal pneumonia. Antimicrob
Agents Chemother. 2004; 48(4):
1105–11.
- Bogdanovich T, Bozdogan B,
Appelbaum PC. Resistance Selection
Studies on Staphylococci with
Ceftobiprole (BAL9141). 44th ICAAC
2004. Poster
E-2018.
- Clark L, Kosowska K, Credito K,
Appelbaum PC. Resistance Selection of
BAL9141, the Active Component of
Prodrug BAL5788, against Pneumococci.
44th ICAAC 2004. Poster
E-2020.
- Deshpande LM, Rhomberg PR,
Fritsche TR, Sader HS and Jones RN.
Bactericidal activity of BAL9141, a
novel parenteral cephalosporin
against contemporary Gram-positive
and Gram-negative isolates. Diagn
Microbiol Infect Dis. 2004; 50(1):
73–5.
- Ednie L, Appelbaum PC.
Antistaphylococcal Activity of
Ceftobiprole (BAL9141) and
Comparators. 44th ICAAC 2004. Poster
E-2021.
- Galm U, Heller S, Shapiro S, Page
M, Li S-M, Heide L. Antimicrobial and
DNA gyrase-inhibitory activities of
novel clorobiocin derivatives
produced by mutasynthesis.
Antimicrobial Agents and Chemotherapy
2004; 48(4):
1307–1312.
- Goodall JJ, Chen GJ, Page MGP.
Essential role of histidine 20 in the
catalytic mechanism of Escherichia
coli peptidyl-tRNA hydrolase.
Biochemistry 2004; 43(15):
4583–4591.
- Guillen J, Bernabeu A, Shapiro S,
Villalain J. Location and orientation
of Triclosan in phospholipid model
membranes. European Biophysics
Journal 2004; 33(5):
448–453.
- Heep M, Querner S, Harsch M,
O'Riordan W. Ceftobiprloe (BAL5788),
the First of a New Class of Anti-MRSA
Cephalosporins: Microbiological
Results from a Phase II Study in
Complicated Skin and Skin Structure
Infections. 44th ICAAC 2004. Poster
L-361.
- Heller S, Marrer E, Page MGP,
Shapiro S, Thenoz L. Development of
endogenous resistance by
staphylococci to BAL9141 and
comparators. 14th ECCMID 2004.
Poster: P675.
- Hoellman D, Jacobs, M.,
Appelbaum, P. MIC determination of
the anti-pneumococcal activity of
BAL9141 compared to other agents.
14th ECCMID 2004. Poster
P537.
- Jacobs MR, Bajaksouzian S, Windau
A, Appelbaum PC. Ceftobiprole
(BAL9141): Activity Against
Staphylococci and Pneumococci by
Microdilution and Etest Methods. 44th
ICAAC. Poster
D-1920.
- Kresken M, Heep M, Wiegand I.
Gram-negative bacteria producing
characterised beta-lactamases: in
vitro activities of BAL9141 and
comparators, 14th ECCMID 2004. Poster
P536.
- Kresken M, Heep M. In vitro
activities of BAL9141 and seven other
beta-lactam antimicrobial agents
towards clinical isolates of 12
members of the Enterobacteriaceae
family. 14th ECCMID 2004. Poster
P1209.
- Kresken M, Heep M. In Vitro
Activities of BAL9141, the Active
Component of BAL5788, and Seven other
Beta-Lactams against Selected Strains
of Pseudomonas aeruginosa Susceptible
or Resistant to Ceftazidime. 14th
ECCMID 2004. Poster
E-2022.
- Lin G, Appelbaum PC. Comparative
Time-Kill Determination of the
Antipneumococcal Activity of
Ceftobiprole (BAL9141). 14th ECCMID
2004. Poster
E-2019.
- Mouton JW, Schmitt-Hoffmann A,
Punt N. Monte Carlo Simulations of
BAL8557: a New Watersoluble Azole
with Antifungal Activity. 44th ICAAC
2004. Poster
A-134.
- Mouton JW, Schmitt-Hoffmann A,
Shapiro S, Nashed N, Punt NC. Use of
Monte Carlo simulations to select
therapeutic doses and provisional
breakpoints of BAL9141. Antimicrob
Agents Chemother. 2004; 48(5):
1713–8.
- Paetzel M, Goodall JJ, Kania M,
Dalbey RE, Page MGP. Crystallographic
and Biophysical Analysis of a
Bacterial Signal Peptidase in Complex
with a Lipopeptide-based Inhibitor.
Journal of Biological Chemistry.
2004; 279(29):
30781–30790.
- Page MG. Cephalosporins in
clinical development. Expert Opin
Investig Drugs. 2004; 13(8):
973–85.
- Reynolds D, Livermore RM.
Comparative Activity of BAL9141,
Daptomycin and Linezolid versus S.
aureus from Bacteremias in the UK and
Ireland. 44th ICAAC 2004. Poster
E-2035.
- Reynolds R, Livermore DM. Effect
of Culture Conditions on MICs of
BAL9141, Representing a New Class of
Cephalosporins Active against MRSA.
44th ICAAC 2004. Abstact
E-2036.
- Rice LB, Bellais S, Carias LL,
Hutton-Thomas R, Bonomo RA, Caspers
P, Page MGP, Gutmann L. Impact of
specific pbp5 mutations on expression
of beta-lactam resistance in
Enterococcus faecium. Antimicrobial
Agents and Chemotherapy 2004; 48(8):
3028–3032.
- Rouse M, Anguita-Alonso P, Hein
MH, Steckelberg JM, Patel R. Activity
of BAL5788 in Haemophilus influenzae,
Enterobacter cloacae or Klebsiella
pneumoniae Experimental Murine
Pneumonia. 44th ICAAC 2004. Poster
B-1177.
- Sader HS, Biedenbach DJ, Jones
RN. Antimicrobial Activity of
BAL9141Tested against Staphylococcal
Strains with Selected Resistance
Patterns. 44th ICAAC 2004. Poster
E-2037.
- Schmitt-Hoffmann A, Nyman L, Roos
B, Schleimer M, Sauer J, Nashed N,
Brown T, Man A, Weidekamm E.
Multiple-dose pharmacokinetics and
safety of a novel broad-spectrum
cephalosporin (BAL5788) in healthy
volunteers. Antimicrob Agents
Chemother. 2004; 48(7):
2576-8.
- Schmitt-Hoffmann A, Roos B, Heep
M, et al. Pharmacokinetics of
BAL4815, a New Azole Antifungal after
Administration of Single Ascending
Intravenous Doses of its Pro-Drug
BAL8557. 14th ECCMID 2004. Poster
P-1033.
- Schmitt-Hoffmann A, Roos B, Heep
M, Schleimer M, Weidekamm E, Man A,
Roehrle M. Pharmacokinetics of
BAL4815, a New Azole Antifungal,
after Administration of Single
Ascending Intravenous Doses of its
Pro-Drug BAL8557. 14th ECCMID 2004.
Poster P1033.
- Schmitt-Hoffmann A, Roos B,
Schleimer M, Sauer J, Man A, Nashed
N, Brown T, Perez A, Weidekamm E,
Kovacs P. Single-dose
pharmacokinetics and safety of a
novel broad-spectrum cephalosporin
(BAL5788) in healthy volunteers.
Antimicrob Agents Chemother. 2004;
48(7):
2570–5.
- Schmitt-Hoffmann A, Roos B,
Spickermann J, Weidekamm E, Roehrle
M. Multiple Ascending Dose
Pharmacokinetics of the New
Antifungal BAL4815 after Intravenous
and Oral Administration of its
Prodrug BAL8557. 44th ICAAC 2004.
Poster A-37.
- Schmitt-Hoffmann AH, Harsch M,
Heep M, Schleimer M, Brown T, Man A,
O'Riordan W. BAL5788 in patients with
complicated skin and skin structure
infections caused by Gram-positive
pathogens including
methicillin-resistant Staphylococcus
species. Interim pharmacokinetic
results from 20 patients, 14th ECCMID
2004. Poster
P1031.
- Schmitt-Hoffmann AH, Roos B, Heep
M, Schleimer M, Weidekamm E, Man A,
Abdou N. Influence of gender on the
pharmacokinetics of BAL9141 after
intravenous infusion of Pro-drug
BAL5788. 14th ECCMID 2004. Poster
P1030.
- Schmitt-Hoffmann AH, Roos B,
Schleimer M, Weidekamm E, Brown T,
Heep M, Man A, Nilsson LG. Dose
adjustment in subjects with normal
and impaired renal function based on
the pharmacokinetics of BAL5788. 14th
ECCMID 2004. Poster
P1032.
- Suzuki T, Nakasato K, Shapiro S,
Pomati F, Neilan, BA. Effects of
synthetic anaesthetics on the growth
of the cyanobacterium Synechococcus
leopoliensis. Journal of Applied
Phycology 2004; 16(2):
145-152.
- Suzuki T, Suzuki K, Shapiro S,
Nagano A. Effects of bioactive
substances on the growth of
lithotrophic ammonia-oxidizing
bacteria. Toyo Daigaku Kiyo, Shizen
Kagaku-hen 2004; 48:
11–18.
- Te Dorsthorst D, Verweij PE, Meis
JF, Mouton JW. Pharmacodynamics of
BAL4815 a new azole antifungal in a
mouse model of systemic infection.
14th ECCMID 2004. Poster
A-1874.
- Vaudaux BP, Gjinovci A, Bento M,
Li D, Francois P, Lew DP, Schrenzel
J. Poster Intensive Therapy with
BAL5788 of Experimental Foreign Body
Infection due to
Methicillin-Resistant Staphylococcus
aureus (MRSA). 44th ICAAC 2004.
Poster B-677.
- Warn P, Sharp A, Denning D, Heep
M, Schmitt-Hoffmann A. In vivo
Activity of a new triazole BAL8557,
the water-soluble prodrug of BAL4815,
in a temporarily neutropenic murine
model of disseminated Aspergillus
flavus. Advances Against
Aspergillosis Conference, San
Francisco,
2004.
- Warn PA, Sharp A, Denning DW. In
Vitro Activity of a New Triazole
BAL4815, the Active Component of
BAL8557 (the Water-Soluble Prodrug)
against Aspergillus spp. 44th ICAAC
2004. Poster F-842.
- Beyer D, Kroll HP, Endermann R,
Schiffer G, Siegel S, Bauser M,
Pohlmann J, Brands M, Ziegelbauer K,
Haebich D, Eymann C, Brotz-Oesterhelt
H. New class of bacterial
phenylalanyl-tRNA synthetase
inhibitors with high potency and
broad-spectrum activity. Antimicrob
Agents Chemother. 2004; 48(2):
525-32.
- Freiberg C, Brunner NA, Schiffer
G, Lampe T, Pohlmann J, Brands M,
Raabe M, Habich D, Ziegelbauer K.
Identification and characterization
of the first class of potent
bacterial acetyl-CoA carboxylase
inhibitors with antibacterial
activity. J Biol Chem. 2004; 279(25):
26066-73.
- Pohlmann J, Brotz-Oesterhelt H. New aminoacyl-tRNA synthetase inhibitors as antibacterial agents. Curr Drug Targets Infect Disord. 2004; 4(4): 261-72.
© 2010 Basilea Pharmaceutica Ltd.
